Collegium Pharmaceutical Inc
Most Recent
What Collegium Pharmaceutical’s Valuation Trend Indicates
Collegium Pharmaceutical’s (COLL) interest income increased from $137,000 in the second quarter of 2017 to $391,000 in the second quarter of 2018.
Surge in Xtampza Sales Bodes Well for Collegium Pharmaceutical
Collegium Pharmaceutical generated total revenues of $73.06 million in the second quarter of 2018 as compared with $3.56 million in the second quarter of 2017.
How Is Insys Therapeutics Positioned in H2 2018?
Insys Therapeutics generated total revenues of $23.46 million in the second quarter of 2018 as compared to $42.58 million in the second quarter of 2017.
